Angiotensin II Type 1 Receptor Antagonist Losartan Inhibits TNF-α-Induced Inflammation and Degeneration Processes in Human Nucleus Pulposus Cells
Authors:
- Babak SaraviBabak Saravi
- Zhen LiZLZhen Li
- Judith PfannkucheJPJudith Pfannkuche
- Laura WystrachLWLaura Wystrach
- Sonja HäckelSHSonja Häckel
- Christoph E. AlbersCAChristoph E. Albers
- Sibylle GradSibylle Grad
- Mauro AliniMAMauro Alini
- Robert Geoffrey RichardsRRRobert Geoffrey Richards
- Corinna LangCLCorinna Lang
- Norbert SüdkampNSNorbert Südkamp
- Hagen SchmalHSHagen Schmal
Open Access
- 4 January 2021
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 11 (1) , 417
Abstract
Our recent study detected the expression of a tissue renin–angiotensin system (tRAS) in human intervertebral discs (IVDs). The present study sought to investigate the impact of the angiotensin II receptor type 1 (AGTR1) antagonist losartan on human nucleus pulposus (NP) cell inflammation and degeneration induced by tumor necrosis factor-α (TNF-α). Human NP cells (4 donors; Pfirrmann grade 2–3; 30–37-years–old; male) were isolated and expanded. TNF-α (10 ng/mL) was used to induce inflammation and degeneration. We examined the impact of losartan supplementation and measured gene expression of tRAS, anabolic, catabolic, and inflammatory markers in NP cells after 24 and 72 h of exposure. T0070907, a PPAR gamma antagonist, was applied to examine the regulatory pathway of losartan. Losartan (1 mM) significantly impaired the TNF-α-induced increase of pro-inflammatory (nitric oxide and TNF-α), catabolic (matrix metalloproteinases), and tRAS (AGTR1a and angiotensin-converting enzyme) markers. Further, losartan maintained the NP cell phenotype by upregulating aggrecan and downregulating collagen type I expression. In summary, losartan showed anti-inflammatory, anti-catabolic, and positive phenotype-modulating effects on human NP cells. These results indicate that tRAS signaling plays an important role in IVD degeneration, and tRAS modulation with losartan could represent a novel therapeutic approach.Keywords
All Related Versions
Funding Information
- German Spine Society (DWG) (Gernot Lang)
- German Arthritis Foundation (Gernot Lang)
- Stiftung zur Förderung der Erforschung von Ersatz- und Ergänzungsmethoden zur Einschränkung von Tierversuchen (number 59)
- AO Foundation (ProtectDisc)
- AOSpine (ProtectDisc)
- Berta-Ottenstein-Programme for Advanced Clinician Scientists (Gernot Lang)
This publication has 76 references indexed in Scilit:
- Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritisArthritis Research & Therapy, 2012
- LPS-Stimulated Cytokine Production in Type I Cells Is Modulated by the Renin–Angiotensin SystemAmerican Journal of Respiratory Cell and Molecular Biology, 2012
- Angiotensin II as a Morphogenic Cytokine Stimulating Renal FibrogenesisJournal of the American Society of Nephrology, 2011
- Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumorsProceedings of the National Academy of Sciences, 2011
- Intraneuronal angiotensinergic system in rat and human dorsal root gangliaRegulatory Peptides, 2010
- Regulation of T-cell function by endogenously produced angiotensin IIAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Angiotensin II Up-Regulates Angiotensin I-Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase PathwayThe American Journal of Pathology, 2008
- Estrogen Elicits Dorsal Root Ganglion Axon Sprouting via a Renin-Angiotensin SystemEndocrinology, 2008
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritisRheumatology, 2004